DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.

Author(s): Harrer A, Wipfler P, Einhaeupl M, Pilz G, Oppermann K, Hitzl W, Afazel S, Haschke-Becher E, Strasser P, Trinka E, Kraus J

Affiliation(s): Christian-Doppler-Klinik, Department of Neurology, Paracelsus Medical University, Salzburg, Austria. a.harrer@salk.at

Publication date & source: 2011-05, J Neuroimmunol., 234(1-2):148-54. Epub 2011 Mar 29.

Publication type: Research Support, Non-U.S. Gov't

Natalizumab interferes with immune cell migration into the central nervous system via blocking the alpha-4 subunit of very-late activation antigen-4 (VLA-4). Occurrence of rare but serious progressive multifocal leukoencephalopathy during prolonged natalizumab therapy of multiple sclerosis (MS) calls for a more detailed understanding of potential coeffects. We longitudinally studied alpha-4 and beta-1 surface levels on blood cells from 18 MS patients by flow cytometry. Expectedly, detectability of natalizumab-blocked alpha-4 was diminished on all investigated cell subsets. In addition, we report a concurrent and significant decrease of beta-1 surface levels on T-cells, B-cells, natural killer cells, and natural killer T cells, but not on monocytes. Uncovering secondary effects of natalizumab is mandatory to increase safety in MS therapy. Copyright (c) 2011 Elsevier B.V. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017